Aptorum Group Ownership

APM Stock  USD 1.61  0.53  24.77%   
The market capitalization of Aptorum Group is $12 Million. Aptorum Group Ltd retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2017-03-31
Previous Quarter
5.2 M
Current Value
5.2 M
Avarage Shares Outstanding
14.2 M
Quarterly Volatility
14 M
 
Covid
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptorum Group Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Aptorum Stock Ownership Analysis

About 24.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aptorum Group had not issued any dividends in recent years. The entity had 1:10 split on the 23rd of January 2023. Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. For more info on Aptorum Group Ltd please contact Darren Lui at 44 20 8092 9299 or go to https://www.aptorumgroup.com.
Besides selling stocks to institutional investors, Aptorum Group also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aptorum Group's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aptorum Group's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Aptorum Group Quarterly Liabilities And Stockholders Equity

20.64 Million

About 24.0% of Aptorum Group Ltd are currently held by insiders. Unlike Aptorum Group's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aptorum Group's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aptorum Group's insider trades

Aptorum Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aptorum Group is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptorum Group Ltd backward and forwards among themselves. Aptorum Group's institutional investor refers to the entity that pools money to purchase Aptorum Group's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-09-30
39.7 K
Morgan Stanley - Brokerage Accounts2024-09-30
16 K
Murchinson Ltd.2024-06-30
0.0
Tower Research Capital Llc2024-06-30
0.0
Goss Wealth Management Llc2024-06-30
0.0
Ubs Group Ag2024-09-30
0.0
Citadel Advisors Llc2024-09-30
0.0
Note, although Aptorum Group's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aptorum Group Outstanding Bonds

Aptorum Group issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aptorum Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aptorum bonds can be classified according to their maturity, which is the date when Aptorum Group Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Aptorum Group Corporate Filings

3rd of January 2025
Other Reports
ViewVerify
6K
20th of December 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
25th of October 2024
Other Reports
ViewVerify
26th of July 2024
Other Reports
ViewVerify

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Aptorum Group is a strong investment it is important to analyze Aptorum Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aptorum Group's future performance. For an informed investment choice regarding Aptorum Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptorum Group Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptorum Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.31
Revenue Per Share
0.095
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.32)
Return On Equity
(0.37)
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptorum Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptorum Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptorum Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.